UBS Group
MITO

UBS Group’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

UBS Group’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-487
Closed – – 11847
2022
Q3 		$0 Sell
487
-28,032
-98% -$7.98K ﹤0.01% 11594
2022
Q2 		$7K Buy
28,519
+26,940
+1,706% +$9.27K ﹤0.01% 8613
2022
Q1 		$1K Buy
1,579
+1,092
+224% +$738 ﹤0.01% 10098
2021
Q4 		$0 Hold
487
– – ﹤0.01% 11148
2021
Q3 		$1K Sell
487
-14,820
-97% -$20.1K ﹤0.01% 9396
2021
Q2 		$24K Buy
15,307
+10,537
+221% +$14.7K ﹤0.01% 7173
2021
Q1 		$8K Buy
4,770
+4,083
+594% +$7.02K ﹤0.01% 8120
2020
Q4 		$1K Sell
687
-7,115
-91% -$9.98K ﹤0.01% 8292
2020
Q3 		$11K Sell
7,802
-7,198
-48% -$12.3K ﹤0.01% 6805
2020
Q2 		$27K Buy
15,000
+14,600
+3,650% +$26.6K ﹤0.01% 6360
2020
Q1 		$1K Sell
400
-6,600
-94% -$14.7K ﹤0.01% 7854
2019
Q4 		$23K Buy
7,000
+286
+4% +$2.19K ﹤0.01% 6802
2019
Q3 		$40K Buy
6,714
+4,633
+223% +$47.4K ﹤0.01% 6327
2019
Q2 		$26K Buy
2,081
+2,016
+3,102% +$27K ﹤0.01% 6450
2019
Q1 		$1K Buy
+65
New +$874 ﹤0.01% 7599

UBS Group's MITO Position: Q4 2022 in Review

UBS Group sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2022, closing a stake of 487 shares.

UBS Group first reported a position in MITO in Q1 2019 and held it in 15 quarters. The position peaked at $40K in Q3 2019. 0 funds tracked by Wall St. Rank hold MITO as of Q4 2022.

  • UBS Group reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 487 Stealth BioTherapeutics Corp. ADS shares in Q4 2022.
  • UBS Group first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2019 and held it in 15 quarters.
  • UBS Group's Stealth BioTherapeutics Corp. ADS position peaked at $40K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.